MP03-Lupus
Precision Medicine / IBS-MP03 / Consolidated
Our group is focused on Cardiovascular Risk in Systemic Autoimmune Diseases.
Research lines
- Physical exercise and SLE
- Cardiovascular risk in other systemic autoimmune diseases other than SLE
- Cardiovascular risk in systemic lupus erythematosus
RICARDO ROA CHAMORRO
PABLO GONZALEZ BUSTOS
FERNANDO JAEN AGUILA
BLANCA GAVILAN CARRERA
JUAN DIEGO MEDIAVILLA GARCIA
NURIA NAVARRETE NAVARRETE
JOSE MARIO SABIO SANCHEZ
JOSE ANTONIO VARGAS MILESTONES
MONICA ZAMORA PAST
ANTONIO DIAZ CHAMORRO
LAURA JAIMEZ GAMIZ
Prescribing statin therapy in physically (in)active individuals vs prescribing physical activity in statin-treated patients: A four-scenario practical approach
PHARMACOLOGICAL RESEARCH, 2023;
FI: 9,3; D1
No Changes in Body Composition and Adherence to the Mediterranean Diet after a 12-Week Aerobic Training Intervention in Women with Systemic Lupus Erythematosus: The EJERCITA-LES Study
NUTRIENTS, 2023;
FI: 5,9; Q1
Panuveitis caused by Listeria monocytogenes
CLINICAL MEDICINE, 2023;
FI: 3,9; Q2
High-sensitivity cardiac troponin I is a biomarker for increased arterial stiffness in systemic lupus erythematous women with normal kidney function
RHEUMATOLOGY INTERNATIONAL, 2023;
FI: 4; Q2
Prevalence and characteristics of systemic autoimmune diseases-related autoantibodies in convalescent patients after SARS-CoV-2 infection
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2023;
FI: 3,7; Q3
Standardized incidence ratios and risk factors for cancer in patients with systemic sclerosis: Data from the Spanish Scleroderma Registry (RESCLE).
AUTOIMMUNITY REVIEWS, 2022;
FI: 17,39; D1
Withdrawal of low-dose prednisone in inactive SLE patients: Is there another alternative?
ANNALS OF THE RHEUMATIC DISEASES, 2022;
FI: 27,973; D1
Assessment of antiphospholipid antibodies during the follow-up of patients after SARS-CoV-2 infection
CLINICAL MEDICINE, 2022;
FI: 3,2; Q2
Effects of 12-week aerobic exercise on patient-reported outcomes in women with systemic lupus erythematosus
DISABILITY AND REHABILITATION, 2022;
FI: 2,439; Q2
Left ventricular diastolic dysfunction in systemic sclerosis: Clinical, immunological and survival differences in the Spanish RESCLE registry.
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2022;
FI: 5,431; Q2
First case of DRESS syndrome caused by hydroxychloroquine with a positive patch test
CONTACT DERMATITIS, 2021;
FI: 6,6; D1
Arterial hypertension assessment in a population with chronic myeloid leukemia
SCIENTIFIC REPORTS, 2021;
FI: 4,38; Q1
Ideal cardiovascular health in women with systemic lupus erythematosus: Association with arterial stiffness, inflammation, and fitness
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021;
FI: 4,164; Q2
Myasthenia gravis and systemic lupus erythematosus: Presentation of 5 cases and PubMed review
NEUROLOGY, 2021;
FI: 3,109; Q3
Persistent symptoms after acute COVID-19 infection: importance of follow-up
CLINICAL MEDICINE, 2021;
FI: 1,725; Q3
Heart Rate Variability in Women with Systemic Lupus Erythematosus: Association with Health-Related Parameters and Effects of Aerobic Exercise.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020;
Comment on: Physical activity, sedentary behavior and their associations with cardiovascular risk in systemic lupus erythematosus
RHEUMATOLOGY, 2020;
FI: 5,606; Q1
Association between homocysteine levels and arterial stiffness in women with systemic sclerosis
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2020;
FI: 3,319; Q2
Longterm Efficacy and Safety of Monotherapy versus Combination Therapy in Systemic Sclerosis-associated Pulmonary Arterial Hypertension: A Retrospective RESCLE Registry Study.
JOURNAL OF RHEUMATOLOGY, 2020;
FI: 3,35; Q2
Physical Exercise following bariatric surgery in women with Morbid obesity Study protocol clinical trial (SPIRIT compliant)
MEDICINE, 2020;
FI: 1,552; Q3
GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways
NATURE COMMUNICATIONS, 2019;
FI: 11,878; D1
Association of physical fitness components and health-related quality of life in women with systemic lupus erythematosus with mild disease activity.
PLOSONE, 2019;
FI: 2,776; Q2
Thrombotic microangiopathy in a patient with eosinophilic granulomatosis with polyangiitis: case-based review
RHEUMATOLOGY INTERNATIONAL, 2019;
FI: 2,2; Q3
Characteristics and safety of tattoos in patients with systemic lupus erythematosus
LUPUS, 2019;
FI: 2,924; Q3
Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry
CLINICAL RHEUMATOLOGY, 2019;
FI: 2,293; Q3
Effects of 12-week Aerobic Exercise on Arterial Stiffness, Inflammation, and Cardiorespiratory Fitness in Women with Systemic LUPUS Erythematosus: Non-Randomized Controlled Trial
JOURNAL OF CLINICAL MEDICINE, 2018;
FI: 5,583; D1
Efficacy of Cognitive Behavioral Therapy in Adherence to the Mediterranean Diet in Metabolic Syndrome Patients: A Randomized Controlled Trial
JOURNAL OF NUTRITION EDUCATION AND BEHAVIOR, 2018;
FI: 2,571; Q1
Hepatobiliary involvement in systemic sclerosis and the cutaneous subsets: Characteristics and survival of patients from the Spanish RESCLE Registry
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2018;
FI: 4,356; Q1
Cardiorespiratory fitness and age-related arterial stiffness in women with systemic lupus erythematosus.
EUROPEAN JOURNAL OF CLINICAL RESEARCH, 2018;
FI: 3,086; Q1
Association of objectively measured physical activity and sedentary time with arterial stiffness in women with systemic lupus erythematosus with mild disease activity.
PLOSONE, 2018;
FI: 2,766; Q1
Systemic inflammation and endothelial dysfunction-a possible link between osteoarthritis and hypertension: comment on the article by Niu et al
ARTHRITIS & RHEUMATOLOGY, 2017;
FI: 6,918; D1
Transancestral mapping and genetic load in systemic lupus erythematosus
NATURE COMMUNICATIONS, 2017;
FI: 12,124; D1
A combined large-scale meta-analysis identifies COG6 as a novel shared risk locus for rheumatoid arthritis and systemic lupus erythernatosus
ANNALS OF THE RHEUMATIC DISEASES, 2017;
FI: 12,811; D1
Exercise for Patients With Hypertrophic Cardiomyopathy
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017;
FI: 44,405; D1
Very early and early systemic sclerosis in the Spanish scleroderma Registry (RESCLE) cohort
AUTOIMMUNITY REVIEWS, 2017;
FI: 8,961; D1
Severe digital necrosis as the clinical onset of antiphospholipid syndrome
INTERNAL AND EMERGENCY MEDICINE, 2016;
FI: 2,34; Q1
Relationship between QT Interval Length and Arterial Stiffness in Systemic Lupus Erythematosus (SLE): A Cross-Sectional Case-Control Study
PLOSONE, 2016;
FI: 3,057; Q1
Leishmaniasis, lupus nephritis and immunosuppressive therapy
QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2016;
FI: 2,824; Q1
Systemic lupus erythematosus today
CLINICAL MEDICINE, 2016;
FI: 1,267; Q2
Cumulated organ damage is associated with arterial stiffness in women with systemic lupus erythematosus irrespective of renal function
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016;
FI: 2,495; Q2
Registry of the Spanish Network for Systemic Sclerosis Survival, Prognostic Factors, and Causes of Death
MEDICINE, 2015;
FI: 5,723; D1
Prevalence of and Factors Associated With Increased Arterial Stiffness in Patients With Primary Sjogren's Syndrome
ARTHRITIS CARE & RESEARCH, 2015;
FI: 4,713; Q1
Effect of mycophenolate mofetil on active hepatitis C virus in a woman with lupus nephritis after two years of follow-up
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015;
FI: 2,724; Q2
Immunomodulatory properties of stem mesenchymal cells in autoimmune diseases
CLINICAL MEDICINE, 2015;
FI: 1,417; Q2
Nighttime Blood Pressure Patterns and Subclinical Atherosclerosis in Women with Systemic Lupus Erythematosus
JOURNAL OF RHEUMATOLOGY, 2015;
FI: 3,187; Q2
UPPA-FH – Deciphering the impact of physical exercise on cardiorespiratory fitness, atherosclerosis and underlying mechanisms in patients with familial hypercholesterolemia
Funder: STATE RESEARCH AGENCY
File number: PID2022-142844OB-I00
Execution time: 01/09/2023 - 31/08/2025
IP: JOSE ANTONIO VARGAS MILESTONES
Effects of a Physical Exercise Program on Subclinical Arteriosclerosis and Inflammation of Patients With Systemic Lupus Erythematosus
Funder: COUNCIL OF HEALTH
File number: PI-0525-2016
Execution time: 01/01/2017 - 31/12/2017
IP: JOSE ANTONIO VARGAS MILESTONES
A multicenter, randomized, double-blind, placebo-controlled study evaluating the effect of inclisiran in the prevention of major adverse cardiovascular events in high-risk patients in primary prevention (VICTORION-1 PRE
Funder: NOVARTIS FARMACEUTICA, SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 16/05/2023 - 30/04/2029
PI: JUAN DIEGO MEDIAVILLA GARCIA
Evaluation of the safety of Edoxaban in elderly patients with frailty criteria.
Funder: POSE
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 24/11/2022 - 31/07/2024
PI: JUAN DIEGO MEDIAVILLA GARCIA
Phase III, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of KBP 5074, an ineralocorticoid receptor antagonist, in subjects with uncontrolled hypertension with moderate or severe chronic kidney disease (stage IIIb/IV ).
Funder: KBP BIOSCIENCES PTE. LTD
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 15/07/2022 - 30/03/2024
PI: JUAN DIEGO MEDIAVILLA GARCIA
Phase 3, double-blind, placebo-controlled, multicenter, randomized study to evaluate the efficacy and safety of ORMD 0801 in patients with type 2 diabetes mellitus with inadequate glycemic control with controlled diet alone or with controlled diet and hypoglycemic agents in monotherapy.
Funder: ORAMED LTD
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 08/06/2022 - 30/08/2023
PI: JUAN DIEGO MEDIAVILLA GARCIA
Phase II, parallel-group, double-blind study with three treatment groups to evaluate the efficacy and safety of finerenone plus empagliflozin compared to finerenone or empagliflozin in participants with chronic kidney disease and type 2 diabetes.
Funder: BAYER CONSUMER CARE AG
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 08/04/2022 - 02/12/2023
PI: JUAN DIEGO MEDIAVILLA GARCIA
Patient preferences about treatment options for high blood pressure
Financing: SPANISH SOCIETY OF ARTERIAL HYPERTENSION
Type of test: INDEPENDENT POST-AUTHORIZATION STUDY
Execution time: 07/05/2021 - 30/12/2021
PI: JUAN DIEGO MEDIAVILLA GARCIA
Single-dose and multiple-dose ascending study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of azp-3601, a synthetic parathyroid hormone analog, in healthy subjects and in subjects with hypoparathyroidism.
Financer: AMOLYT PHARMA SAS
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 26/03/2021 - 30/01/2022
PI: JUAN DIEGO MEDIAVILLA GARCIA
Observational study to evaluate the clinical management and the adequacy of the therapeutic strategies used in patients with stable atherosclerotic disease and the use of recommended treatments according to clinical guidelines. (APALUSE STUDY
Funder: CASA DEL CORAZON FOUNDATION
Type of test: INDEPENDENT POST-AUTHORIZATION STUDY
Execution time: 17/01/2020 - 30/09/2020
PI: JUAN DIEGO MEDIAVILLA GARCIA
Multi-center, blinded, randomized, PaRallEl-group, Phase 3 study with aproCltentan in Subjects with Resistant Hypertension (RHT)
Funder: IDORSIA PHARMACEUTICALS LTD
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 25/06/2020 - 30/03/2022
PI: JUAN DIEGO MEDIAVILLA GARCIA
ReFineDR: Observational study of Routine ophthalmological tests of patients included in the two Phase 3 clinical trials, promoted by Bayer, FIDELIO and FIGARO to investigate the effect of Fineronone in delaying the progression of Retinop
Funder: BAYER AG
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 17/09/2020 - 30/03/2021
PI: JUAN DIEGO MEDIAVILLA GARCIA
Treatment of dyslipidemic patients with high or very high risk for the prevention of cardiovascular events in Europe -Multinational Observational Study.
Funder: DAIICHI SANKYO EUROPE GMBH
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 08/10/2020 - 30/12/2022
PI: JUAN DIEGO MEDIAVILLA GARCIA
Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the safety and efficacy of individually adjusted oral doses of runcaciguat in subjects with a clinical diagnosis of chronic renal failure with diabetes and / or hypertension.
Funder: BAYER AG
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 18/05/2020 - 12/09/2021
PI: JUAN DIEGO MEDIAVILLA GARCIA
Randomized, double-blind, placebo-controlled study of the safety and efficacy of different doses and regimens of evinacumab in patients with chronic hypercholesterolaemia despite maximum tolerated lipid-lowering therapy.
Funder: REGENERON PHARMACEUTICALS, INC
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 15/05/2018 - 30/12/2020
PI: JUAN DIEGO MEDIAVILLA GARCIA